{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT02579811","nct_id":"NCT02579811","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02579811. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.","label":"Axitinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-06-20","type":"ACTUAL"},"conditions":["Metastatic Renal Cell Cancer"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Axitinib","otherNames":[],"type":"DRUG"}],"last_update":"2023-06-29","lead_sponsor":"Case Comprehensive Cancer Center","official_title":"A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2019-08-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Median Progression-free Survival","timeFrame":"Up to 18 months"}],"references":[{"citation":"Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2019 Oct;20(10):1386-1394. doi: 10.1016/S1470-2045(19)30513-3. Epub 2019 Aug 16.","pmid":"31427205","type":"DERIVED"}],"start_date":{"date":"2015-12-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer","url":"https://clinicaltrials.gov/study/NCT02579811"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02579811"}